Spots Global Cancer Trial Database for FUSCC Refractory TNBC Platform Study (FUTURE2.0)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Official Title: Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）

Study ID: NCT05749588

Conditions

Triple-negative Breast Cancer

Interventions

A1: SHR-A1811

A2: SHR-A1811 with Camrelizumab

B1: TROP2 ADC

B2: TROP2 ADC with Camrelizumab

C1: SHR-A1811

C2: SHR-A1811 with BP102

D1: TROP2 ADC

D2: TROP2 ADC with BP102

Study Description

Brief Summary: This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.

Detailed Description: This is a Phase II, open-label, Single-center platform study，Based on FUSCC four TNBC subtypes and the results of the previous FUTURE trial, the investigators designed this platform trial, which for combined the TNBC subtyping and genomic sequencing-guided precision targeted therapy for refractory metastatic TNBC patients. In this trial, refractory mTNBC patients eligible for inclusion can be divided into various precision treatment group according to molecular typing and subtyping to evaluate the efficacy and safety of multiple precision targeted treatment. The research therapy arm can be updated with the update of basic translational research in our center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs.